New analyses from FIBRONEER™ trials suggest survival benefit with nerandomilast in IPF and PPF
Not intended for UK and US audiences Nerandomilast long-term survival modeling presented at American Thoracic Society (ATS) 2026 and European Alliance of Associations for Rheumatology (EULAR) 2026 international congresses. Based on the modeling, nerandomilast consistently increased median survival in both idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF).1,2 Modeling predicts meaningful extensions in survival […]
Original Source
Read the full article at Financialpost →KhanList aggregates and links to publicly available news content. We do not host full articles from third-party sources. Always verify important information with original sources.